Literature DB >> 10903931

Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.

Z Deng1, J H Morse, S L Slager, N Cuervo, K J Moore, G Venetos, S Kalachikov, E Cayanis, S G Fischer, R J Barst, S E Hodge, J A Knowles.   

Abstract

Familial primary pulmonary hypertension is a rare autosomal dominant disorder that has reduced penetrance and that has been mapped to a 3-cM region on chromosome 2q33 (locus PPH1). The phenotype is characterized by monoclonal plexiform lesions of proliferating endothelial cells in pulmonary arterioles. These lesions lead to elevated pulmonary-artery pressures, right-ventricular failure, and death. Although primary pulmonary hypertension is rare, cases secondary to known etiologies are more common and include those associated with the appetite-suppressant drugs, including phentermine-fenfluramine. We genotyped 35 multiplex families with the disorder, using 27 microsatellite markers; we constructed disease haplotypes; and we looked for evidence of haplotype sharing across families, using the program TRANSMIT. Suggestive evidence of sharing was observed with markers GGAA19e07 and D2S307, and three nearby candidate genes were examined by denaturing high-performance liquid chromatography on individuals from 19 families. One of these genes (BMPR2), which encodes bone morphogenetic protein receptor type II, was found to contain five mutations that predict premature termination of the protein product and two missense mutations. These mutations were not observed in 196 control chromosomes. These findings indicate that the bone morphogenetic protein-signaling pathway is defective in patients with primary pulmonary hypertension and may implicate the pathway in the nonfamilial forms of the disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10903931      PMCID: PMC1287532          DOI: 10.1086/303059

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  35 in total

1.  Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group.

Authors:  L Abenhaim; Y Moride; F Brenot; S Rich; J Benichou; X Kurz; T Higenbottam; C Oakley; E Wouters; M Aubier; G Simonneau; B Bégaud
Journal:  N Engl J Med       Date:  1996-08-29       Impact factor: 91.245

Review 2.  The molecular basis of lung morphogenesis.

Authors:  D Warburton; M Schwarz; D Tefft; G Flores-Delgado; K D Anderson; W V Cardoso
Journal:  Mech Dev       Date:  2000-03-15       Impact factor: 1.882

3.  cDNA cloning and genomic organization of the mouse BMP type II receptor.

Authors:  H Beppu; O Minowa; K Miyazono; M Kawabata
Journal:  Biochem Biophys Res Commun       Date:  1997-06-27       Impact factor: 3.575

4.  Parametric and nonparametric linkage analysis: a unified multipoint approach.

Authors:  L Kruglyak; M J Daly; M P Reeve-Daly; E S Lander
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

5.  Detection of numerous Y chromosome biallelic polymorphisms by denaturing high-performance liquid chromatography.

Authors:  P A Underhill; L Jin; A A Lin; S Q Mehdi; T Jenkins; D Vollrath; R W Davis; L L Cavalli-Sforza; P J Oefner
Journal:  Genome Res       Date:  1997-10       Impact factor: 9.043

6.  Vascular MADs: two novel MAD-related genes selectively inducible by flow in human vascular endothelium.

Authors:  J N Topper; J Cai; Y Qiu; K R Anderson; Y Y Xu; J D Deeds; R Feeley; C J Gimeno; E A Woolf; O Tayber; G G Mays; B A Sampson; F J Schoen; M A Gimbrone; D Falb
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

7.  Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32.

Authors:  J H Morse; A C Jones; R J Barst; S E Hodge; K C Wilhelmsen; T G Nygaard
Journal:  Circulation       Date:  1997-06-17       Impact factor: 29.690

8.  Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32.

Authors:  W C Nichols; D L Koller; B Slovis; T Foroud; V H Terry; N D Arnold; D R Siemieniak; L Wheeler; J A Phillips; J H Newman; P M Conneally; D Ginsburg; J E Loyd
Journal:  Nat Genet       Date:  1997-03       Impact factor: 38.330

9.  Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2.

Authors:  D W Johnson; J N Berg; M A Baldwin; C J Gallione; I Marondel; S J Yoon; T T Stenzel; M Speer; M A Pericak-Vance; A Diamond; A E Guttmacher; C E Jackson; L Attisano; R Kucherlapati; M E Porteous; D A Marchuk
Journal:  Nat Genet       Date:  1996-06       Impact factor: 38.330

10.  Single lung transplantation for pulmonary hypertension. Single institution experience in 34 patients.

Authors:  M K Pasque; E P Trulock; J D Cooper; A N Triantafillou; C B Huddleston; M Rosenbloom; S Sundaresan; J L Cox; G A Patterson
Journal:  Circulation       Date:  1995-10-15       Impact factor: 29.690

View more
  299 in total

Review 1.  Pulmonary arterial hypertension: new ideas and perspectives.

Authors:  N Galiè; A Torbicki
Journal:  Heart       Date:  2001-04       Impact factor: 5.994

Review 2.  Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension.

Authors:  Ezequiel Balmori Melian; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Recommendations on the management of pulmonary hypertension in clinical practice.

Authors: 
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

Review 4.  The genetics of systemic sclerosis.

Authors:  Randall W Johnson; Monty B Tew; Frank C Arnett
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

Review 5.  Linking a serotonin transporter polymorphism to vascular smooth muscle proliferation in patients with primary pulmonary hypertension.

Authors:  M Rabinovitch
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 6.  New insights into the pathogenesis and treatment of primary pulmonary hypertension.

Authors:  N Rudarakanchana; R C Trembath; N W Morrell
Journal:  Thorax       Date:  2001-11       Impact factor: 9.139

7.  Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension.

Authors:  Rubin M Tuder; Laura A Davis; Brian B Graham
Journal:  Am J Respir Crit Care Med       Date:  2011-11-10       Impact factor: 21.405

8.  The immunophilin FKBP12 inhibits hepcidin expression by binding the BMP type I receptor ALK2 in hepatocytes.

Authors:  Silvia Colucci; Alessia Pagani; Mariateresa Pettinato; Irene Artuso; Antonella Nai; Clara Camaschella; Laura Silvestri
Journal:  Blood       Date:  2017-09-01       Impact factor: 22.113

9.  Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia.

Authors:  R E Harrison; J A Flanagan; M Sankelo; S A Abdalla; J Rowell; R D Machado; C G Elliott; I M Robbins; H Olschewski; V McLaughlin; E Gruenig; F Kermeen; M Halme; A Räisänen-Sokolowski; T Laitinen; N W Morrell; R C Trembath
Journal:  J Med Genet       Date:  2003-12       Impact factor: 6.318

10.  Induction of pulmonary hypertension by an angiopoietin 1/TIE2/serotonin pathway.

Authors:  Christopher C Sullivan; Lingling Du; Danny Chu; Augustine J Cho; Masakuni Kido; Paul L Wolf; Stuart W Jamieson; Patricia A Thistlethwaite
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.